

(14) How many years have you been involved in toxic substance/environmental health issues?

____ Years

(15) How many hours per month on average can you make available for telephone calls, periodic meetings, a review of materials?

____ Hours per month

(16) Have you in the past or are you now participating in an advisory group similar in structure to the Community/Tribal Subcommittee?

____ Yes

____ No

(16a) If yes, please describe the group and your role

(17) **QUALIFICATIONS/BACKGROUND:** Please briefly note your knowledge of/experience with toxic substance/environmental health issues. List relevant self-education/ research, workshops attended, and/or formal training.

(18) **CURRENT ISSUES:** What are your views on ATSDR's current approach to working with communities/tribes?

(19) **EXPECTATIONS:** What type of input, recommendations, and advice do you envision the Subcommittee providing, and what type of outreach would you intend to do in order to formulate your recommendations to the Board of Scientific Counselors?

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee

management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 7, 1999.

John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99-32149 Filed 12-10-99; 8:45 am]

BILLING CODE 4163-70-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Education Programs in Occupational Safety and Health To Prepare Health Services Researchers, Program Announcement 00012

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Education Programs in Occupational Safety and Health to Prepare Health Services Researchers, Program Announcement 00012, meeting.

Times and Dates: 8 a.m.-9 a.m., January 10, 2000 (Open); 9 a.m.-5 p.m., January 10, 2000 (Closed); 8 a.m.-5 p.m., January 11, 2000 (Closed).

Place: Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, Ga., Building 16, Room 1111.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 00012.

Contact Person for More Information: Bernadine Kuchinski, Occupational Health Consultant, National Institute for Occupational Safety and Health, Office of Extramural Programs, CDC, 1600 Clifton Road, N.E., m/s D30 Atlanta, Georgia 30333. Telephone 404/639-3342, e-mail bbk1@cdc.gov.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 7, 1999.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 99-32148 Filed 12-10-99; 8:45 am]

BILLING CODE 4163-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Mine Safety and Health Research Advisory Committee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following committee meeting.

Name: Mine Safety and Health Research Advisory Committee (MSHRAC).

Time and Date: 9 a.m.-4 p.m., January 6, 2000.

Place: The Washington Court, 525 New Jersey Avenue, NW, Washington, DC 20001-1527.

Status: Open to the public, limited only by space available. The meeting room accommodates approximately 50 people.

Purpose: The Committee is charged with advising the Secretary; the Assistant Secretary for Health and Surgeon General; the Director, Centers for Disease Control and Prevention (CDC); and the Director, National Institute for Occupational Safety and Health, CDC, on priorities in mine safety and health research, including grants and contracts for such research, 30 U.S.C. 812(b)(2), Section 102(b)(2).

Matters to be Discussed: Agenda items include the Director's comments; Report from Associate Director-Mining; Mine Safety and Health Administration's Program to Eliminate Black Lung; Update on Dust Monitors; Hearing Loss Prevention Research at Pittsburgh Research Laboratory; Coal Diesel Partnership Status; Activity to Help Weakened State of Mining Schools; and future activities of the Committee.

Agenda items are subject to change as priorities dictate.

Contact person for more information: Larry Grayson, Ph.D., Executive Secretary, MSHRAC, NIOSH, CDC, 200 Independence Avenue, SW, Room 715-H, Humphrey Building, Washington, DC 20201, telephone 202/401-2192, fax 202/260-4464.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 7, 1999.

John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99-32150 Filed 12-10-99; 8:45 am]

BILLING CODE 4163-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96F-0293]

Avecia Inc.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 6B4516) proposing that the food additive regulations be amended to provide for the safe use of 2-methyl-4,5-trimethylene-4-isothiazolin-3-one as a preservative for paper and paperboard coatings used in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3081.

SUPPLEMENTARY INFORMATION: In a notice published in the *Federal Register* of August 27, 1996 (61 FR 44067), FDA announced that a food additive petition (FAP 6B4516) had been filed by Zeneca Inc., Foulkstone 1405, 2d, 1800 Concord Pike, Wilmington, DE 19850-5457. The petition proposed to amend the food additive regulations in § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of 2-methyl-4,5-trimethylene-4-isothiazolin-3-one as a preservative for paper and paperboard coatings used in contact with food. Since publication of the filing notice, Zeneca Inc.'s, specialty chemicals group has been spun-off to form a new company, Avecia Inc., 1405 Foulk Rd., Wilmington, DE 19850-5457. Avecia Inc., has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: November 29, 1999.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 99-32100 Filed 12-10-99; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 15, 1999, 9 a.m. to 4:30 p.m.

Location: Corporate Bldg., conference room 20B, 9200 Corporate Blvd., Rockville, MD.

Contact Person: Michelle Y. Stuart, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-594-1293, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12515. Please call the Information Line for up-to-date information on this meeting.

Procedure: On December 15, 1999, from 9 a.m. to 10 a.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 13, 1999. Those desiring to make formal oral presentations should notify the contact person by December 13, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Time allotted for the presentations may be limited.

Closed Committee Deliberations: On December 15, 1999, from 10 a.m. to 4:30 p.m., the meeting will be closed to the public. The committee will hear and review trade secret and/or confidential commercial information on a product development protocol (5 U.S.C. 552b(c)(4)). This portion of the meeting

is closed to permit discussion of this information.

FDA regrets that it was unable to publish this notice 15 days prior to the December 15, 1999, Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 7, 1999.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 99-32239 Filed 12-8-99; 4:55 pm]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA-3029-N]

Medicare Program; Meeting of the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee—January 19 and 20, 2000

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meeting.

SUMMARY: This notice announces a public meeting of the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee (MCAC). The panel provides advice and recommendations to the agency about clinical coverage issues. The panel will hear and discuss presentations from interested persons regarding behavioral interventions (pelvic muscle rehabilitation) for the management of non-neurogenic urinary incontinence in adults. The meeting will primarily focus on two management options: biofeedback and pelvic floor electrical stimulation. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)).

DATES:

The Meeting: The meeting will be held on January 19, 2000 from 8:30 a.m. until 5 p.m., E.D.T., and on January 20, 2000, from 8:30 a.m. until 3:00 p.m., E.D.T.